Amortized Payments For High-Cost Drugs Won't Work, Insurer CEOs Say
This article was originally published in The Pink Sheet Daily
The idea raised by health policy experts that high-cost drugs could be paid for in installments over a number of years doesn't appeal to insurance executives at recent conference.
You may also be interested in...
Payors need to adopt a longer-term focus on coverage policies for prescription drugs and biologics that recognizes the benefits of covering high-priced, but often curative, treatments like those for hepatitis C, panelists argue at AEI-sponsored event.
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.